{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "40db9eaf",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd \n",
    "import numpy as np\n",
    "import os, sys\n",
    "from tqdm import tqdm\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n",
    "while os.getcwd().split('/')[-1] != 'rag-llm-cancer-paper':\n",
    "    os.chdir('..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "fdb68ff7",
   "metadata": {},
   "outputs": [],
   "source": [
    "# ================== GENERAL IMPORTS ==================\n",
    "import os\n",
    "import json\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# ================== UTIL FUNCTIONS ==================\n",
    "from utils.embedding import retrieve_context, get_text_embedding, store_embedding #get_context_db,\n",
    "from utils.prompt import get_prompt\n",
    "from llm.run_RAGLLM import run_RAG\n",
    "\n",
    "# Generate context vector database\n",
    "def get_context_db(context_chunks, CLIENT, model_embed):\n",
    "    context_embeddings=np.array([get_text_embedding(chunk, CLIENT, model_embed) for chunk in context_chunks])\n",
    "    index=store_embedding(context_embeddings)\n",
    "    return(index)\n",
    "\n",
    "\n",
    "# ================== MODEL & API IMPORTS ==================\n",
    "from mistralai.client import MistralClient\n",
    "from openai import OpenAI\n",
    "from llm.inference import run_llm\n",
    "import faiss"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4f29dbae",
   "metadata": {},
   "source": [
    "for the sake of thi immediate test, brute force adapt the `run_RAGLLM.py` script. we'll introduce it once it's stable."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "d27a7e49",
   "metadata": {},
   "outputs": [],
   "source": [
    "#setup env\n",
    "load_dotenv()\n",
    "_MODEL = 'gpt-4.1-nano' #this could be gpt-4o-2024-05-13, gpt-4o-mini-2024-07-18, etc.\n",
    "_MODEL_EMBED = 'text-embedding-3-small'\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "if not api_key:\n",
    "    raise ValueError(\"Missing API key. Please set OPENAI_API_KEY in your .env file.\")\n",
    "CLIENT=OpenAI(api_key=api_key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "c4e3ca5c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# #_VERSION = get_local_version()\n",
    "# _QUERY_DF=pd.read_csv('data/real_world_db/real_world_validation__v1.csv', index_col = 0)#pd.read_csv(args.csv_path, index_col=0)\n",
    "# with open(args.context_chunks, \"r\") as f:\n",
    "#     _CONTEXT = json.load(f)\n",
    "# _INDEX = faiss.read_index(f\"./data/latest_db/indexes/text-embedding-3-small_structured_context__{_VERSION}.faiss\")\n",
    "# # Load entity database\n",
    "# with open(f\"context_retriever/entities/moalmanac_db_ner_entities__{_VERSION}.json\", \"r\") as f:\n",
    "#     _DB_ENTITY = json.load(f)\n",
    "# with open(f\"context_retriever/entities/synthetic_query_ner_entities__{_VERSION}.json\", \"r\") as f:\n",
    "#     _QUERY_ENTITY = json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "61c8f97d",
   "metadata": {},
   "outputs": [],
   "source": [
    "_VERSION = '2025-09-04'\n",
    "version = '2025-09'\n",
    "_QUERY_DF=pd.read_csv('data/real_world_db/real_world_validation__v1.csv', index_col = 0)\n",
    "context_json_path=f\"external-validation/non-moa-database/oncokb/oncokb-db/synthetic_answers__{version}.json\"\n",
    "with open(context_json_path, \"r\") as f:\n",
    "     _CONTEXT = json.load(f)\n",
    "index_path = 'external-validation/non-moa-database/oncokb/oncokb-db/index/oncokb_2025-09_structured_context.faiss'\n",
    "_INDEX = faiss.read_index(index_path)\n",
    "with open(f\"context_retriever/entities/oncokb_db_context_ner_entities__oncokb-202509.json\", \"r\") as f:\n",
    "     _DB_ENTITY = json.load(f)\n",
    "with open(f\"context_retriever/entities/real_world_query_ner_entities__v1.json\", \"r\") as f:\n",
    "    _QUERY_ENTITY = json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "0a6358ac",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time elapsed for iteration 0: 0.2958 min\n"
     ]
    }
   ],
   "source": [
    "# Run RAG-LLM iterations\n",
    "from llm.run_RAGLLM import run_iterations_rag\n",
    "output_ls, input_ls, runtime_ls = run_iterations_rag(\n",
    "    num_iterations=1,#args.num_iter, \n",
    "    data=_QUERY_DF, \n",
    "    context_chunks=_CONTEXT, \n",
    "    db_entity=_DB_ENTITY,\n",
    "    query_entity=_QUERY_ENTITY, \n",
    "    num_vec=10, \n",
    "    index=_INDEX,\n",
    "    client=CLIENT, \n",
    "    model=_MODEL, \n",
    "    model_embed=_MODEL_EMBED, \n",
    "    model_type='gpt',\n",
    "    strategy=5,\n",
    "    max_len=None, \n",
    "    temp=0.0, \n",
    "    random_seed=None\n",
    "    )\n",
    "\n",
    "# Save results\n",
    "res_dict = {\n",
    "    \"full output\": output_ls, \n",
    "    \"input prompt\": input_ls, \n",
    "    #\"retrieval\": retrieval_ls,\n",
    "    \"runtime\": runtime_ls\n",
    "    }\n",
    "\n",
    "os.makedirs('external-validation/non-moa-database/oncokb/rag-llm/real-world-query', exist_ok=True)\n",
    "output_dir = 'external-validation/non-moa-database/oncokb/rag-llm/real-world-query'\n",
    "\n",
    "result_file=os.path.join(\n",
    "    output_dir,\n",
    "    f'RAGstra{str(5)}n{str(1)}temp{str(0)}_res_dict.pkl'\n",
    ")\n",
    "from utils.io import save_object\n",
    "save_object(res_dict, filename=result_file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "b32dcfb7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time elapsed for iteration 0: 0.2972 min\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "([['{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Cholangiocarcinoma\",\\n    \"Disease Phase or Condition\": \"metastatic\",\\n    \"Drug Name\": \"pemigatinib\",\\n    \"Prior Treatment or Resistance Status\": \"progressed on standard first-line treatments\",\\n    \"Genomic Features\": \"FGFR2 fusion\",\\n    \"FDA-approval status\": \"FDA-approved\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/pemigatinib\"\\n  }\\n}',\n",
       "   '{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\\n}',\n",
       "   '{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\\n}',\n",
       "   '{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\\n}',\n",
       "   '{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Medullary Thyroid Cancer\",\\n    \"Disease Phase or Condition\": \"progressive or metastatic\",\\n    \"Drug Name\": \"selpercatinib\",\\n    \"Prior Treatment or Resistance Status\": \"none specified\",\\n    \"Genomic Features\": \"RET mutation\",\\n    \"FDA-approval status\": \"FDA-approved\",\\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213644s000lbl.pdf\"\\n  }\\n}',\n",
       "   '{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Pancreatic Adenocarcinoma\",\\n    \"Disease Phase or Condition\": \"metastatic or unresectable, progressed after chemotherapy\",\\n    \"Drug Name\": \"zenocutuzumab\",\\n    \"Prior Treatment or Resistance Status\": \"progressed after at least one line of chemotherapy\",\\n    \"Genomic Features\": \"NRG1 gene fusion\",\\n    \"FDA-approval status\": \"not explicitly specified in the provided data\",\\n    \"Link to FDA-approved Label\": \"N/A\"\\n  }\\n}',\n",
       "   '{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\\n}',\n",
       "   '{\\n  \"Status\": \"success\",\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Bladder Cancer\",\\n    \"Disease Phase or Condition\": \"metastatic, progressed on chemotherapy\",\\n    \"Drug Name\": \"pembrolizumab, trastuzumab, chemotherapy\",\\n    \"Prior Treatment or Resistance Status\": \"progressed on chemotherapy\",\\n    \"Genomic Features\": \"focal amplification of the jak2/pd-l1 locus\",\\n    \"FDA-approval status\": \"FDA-approved for bladder cancer with specific genomic alterations\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab\"\\n  }\\n}',\n",
       "   '{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\\n}',\n",
       "   '{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\\n}',\n",
       "   '{\\n  \"Status\": \"no_match\",\\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\\n}',\n",
       "   '{\\n    \"Status\": \"no_match\",\\n    \"Message\": \"No drugs are FDA-approved for the provided context\"\\n}']],\n",
       " [['\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Cholangiocarcinoma cancer has fusions, one recommended therapy is futibatinib.\\', \\'If a patient with Cholangiocarcinoma cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Cholangiocarcinoma cancer has oncogenic mutations, one recommended therapy is lirafugratinib.\\', \\'If a patient with Cholangiocarcinoma cancer has r132s,r132l,r132c,r132h,r132g, one recommended therapy is ivosidenib.\\', \\'If a patient with Intrahepatic Cholangiocarcinoma cancer has r132s,r132l,r132c,r132h,r132g, one recommended therapy is ivosidenib.\\', \\'If a patient with All Solid Tumors cancer has amplification, one recommended therapy is lirafugratinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is fedratinib.\\', \\'If a patient with All Solid Tumors cancer has oncogenic mutations, one recommended therapy is lirafugratinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Pancreatic Cancer cancer has fusions, one recommended therapy is erdafitinib.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: i have a patient with metastatic cholangiocarcinoma and an fgfr2 fusion. this patient has already progressed on standard first-line treatments. are there any approved therapies i should consider?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Neuroblastoma cancer has r1275q, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has r1275l, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1174c, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1174l, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1245v, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1245y, one recommended therapy is lorlatinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is alectinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has i1171n, one recommended therapy is alectinib.\\', \\'If a patient with Inflammatory Myofibroblastic Tumor cancer has fusions, one recommended therapy is alectinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is nvl-655.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: a patient with relapsed high-risk neuroblastoma has alk mutation x. should they receive an alk inhibitor, and if so, which one?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with APL with PML-RARA cancer has pml-rara fusion, one recommended therapy is tretinoin.\\', \\'If a patient with APL with PML-RARA cancer has pml-rara fusion, one recommended therapy is tretinoin,arsenic trioxide.\\', \\'If a patient with APL with PML-RARA cancer has pml-rara fusion, one recommended therapy is arsenic trioxide.\\', \\'If a patient with APL with PML-RARA cancer has pml-rara fusion, one recommended therapy is arsenic trioxide.\\', \\'If a patient with Mastocytosis cancer has d816, one recommended therapy is avapritinib.\\', \\'If a patient with Histiocytosis cancer has v600, one recommended therapy is dabrafenib.\\', \\'If a patient with Neuroblastoma cancer has f1245v, one recommended therapy is lorlatinib.\\', \\'If a patient with Glioma cancer has amplification, one recommended therapy is lapatinib.\\', \\'If a patient with Melanoma cancer has v600, one recommended therapy is vemurafenib,atezolizumab,cobimetinib.\\', \\'If a patient with Histiocytosis cancer has v600, one recommended therapy is vemurafenib.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: for a patient with relapsed b-all that expresses cd19, what targeted treatment options exist?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Colorectal Cancer cancer has g12c, one recommended therapy is adagrasib,cetuximab.\\', \\'If a patient with Colorectal Cancer cancer has g12c, one recommended therapy is sotorasib,cetuximab.\\', \\'If a patient with Colorectal Cancer cancer has g12c, one recommended therapy is adagrasib,panitumumab.\\', \\'If a patient with Colorectal Cancer cancer has g12c, one recommended therapy is sotorasib,panitumumab.\\', \\'If a patient with Anal Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Ampullary Cancer cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Small Bowel Cancer cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Ampullary Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Colorectal Cancer cancer has oncogenic mutations, one recommended therapy is cetuximab.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: what drug combination is approved for adults with kras g12c-mutated advanced colorectal cancer who have progressed on chemotherapy?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Medullary Thyroid Cancer cancer has oncogenic mutations, one recommended therapy is selpercatinib.\\', \\'If a patient with Medullary Thyroid Cancer cancer has oncogenic mutations, one recommended therapy is pralsetinib.\\', \\'If a patient with Thyroid Cancer cancer has fusions, one recommended therapy is selpercatinib.\\', \\'If a patient with Thyroid Cancer cancer has fusions, one recommended therapy is pralsetinib.\\', \\'If a patient with All Solid Tumors cancer has fusions, one recommended therapy is selpercatinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is fedratinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is ruxolitinib.\\', \\'If a patient with Anaplastic Thyroid Cancer cancer has v600e, one recommended therapy is dabrafenib,trametinib.\\', \\'If a patient with All Solid Tumors cancer has fusions, one recommended therapy is repotrectinib.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: if a patient with progressive or metastatic medullary thyroid cancer needs systemic therapy and the tumor has a ret mutation, what is preferred first line treatment?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Pancreatic Adenocarcinoma cancer has fusions, one recommended therapy is zenocutuzumab.\\', \\'If a patient with Acinar Cell Carcinoma of the Pancreas cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with All Solid Tumors cancer has fusions, one recommended therapy is zenocutuzumab.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12d, one recommended therapy is asp3082.\\', \\'If a patient with Acinar Cell Carcinoma of the Pancreas cancer has oncogenic mutations, one recommended therapy is olaparib.\\', \\'If a patient with Acinar Cell Carcinoma of the Pancreas cancer has oncogenic mutations, one recommended therapy is olaparib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with Acinar Cell Carcinoma of the Pancreas cancer has oncogenic mutations, one recommended therapy is rucaparib.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: my patient with metastatic or unresectable pancreatic adenocarcinoma has progressed on at least one line of chemotherapy and was found to have an nrg1 gene fusion via somatic tumor testing. what options are there for subsequent treatment?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Inflammatory Myofibroblastic Tumor cancer has fusions, one recommended therapy is alectinib.\\', \\'If a patient with Inflammatory Myofibroblastic Tumor cancer has fusions, one recommended therapy is ceritinib.\\', \\'If a patient with Inflammatory Myofibroblastic Tumor cancer has fusions, one recommended therapy is brigatinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is ceritinib.\\', \\'If a patient with All Solid Tumors cancer has fusions, one recommended therapy is crizotinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is alectinib.\\', \\'If a patient with Neuroblastoma cancer has f1174c, one recommended therapy is lorlatinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is ceritinib.\\', \\'If a patient with Neuroblastoma cancer has r1275q, one recommended therapy is lorlatinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is ensartinib.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: are alk inhibitors approved for use in tfcp2 fusion positive rhabdomyosarcoma?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Bladder Cancer cancer has oncogenic mutations, one recommended therapy is tazemetostat.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Bladder Cancer cancer has oncogenic mutations, one recommended therapy is cisplatin.\\', \\'If a patient with Esophagogastric Adenocarcinoma cancer has amplification, one recommended therapy is pembrolizumab,trastuzumab,chemotherapy.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is ruxolitinib.\\', \\'If a patient with Bladder Cancer cancer has oncogenic mutations, one recommended therapy is erdafitinib.\\', \\'If a patient with Bladder Cancer cancer has oncogenic mutations, one recommended therapy is erdafitinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is fedratinib.\\', \\'If a patient with Melanoma cancer has v600, one recommended therapy is vemurafenib,atezolizumab,cobimetinib.\\', \\'If a patient with Bladder Cancer cancer has e2014k,e2419k, one recommended therapy is everolimus.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: i have a patient with metastatic bladder cancer who has progressed on chemotherapy. genomics testing revealed a focal amplification of the jak2/pd-l1 locus. what are the treatment options?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Pancreatic Adenocarcinoma cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Ampullary Cancer cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Ampullary Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12a,g12d,g12r,g12s,g12v, one recommended therapy is daraxonrasib.\\', \\'If a patient with Small Bowel Cancer cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Small Bowel Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12d, one recommended therapy is asp3082.\\', \\'If a patient with Anal Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Tubular Adenoma of the Colon cancer has g12c, one recommended therapy is adagrasib.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: for a patient with lung adenocarcinoma and a kras g12c mutation, what targeted treatments are approved and for what stage?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Oligodendroglioma cancer has r172k,r172m,r172s,r172w,r172g, one recommended therapy is vorasidenib.\\', \\'If a patient with Astrocytoma cancer has r172k,r172m,r172s,r172w,r172g, one recommended therapy is vorasidenib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is ruxolitinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is fedratinib.\\', \\'If a patient with All Solid Tumors cancer has f617l, one recommended therapy is larotrectinib.\\', \\'If a patient with Neuroblastoma cancer has r1275q, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1174l, one recommended therapy is lorlatinib.\\', \\'If a patient with All Solid Tumors cancer has g696a, one recommended therapy is larotrectinib.\\', \\'If a patient with All Solid Tumors cancer has amplification, one recommended therapy is blu-222.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: what can target high grade wilms tumor with wt1 mutation\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is olaparib.\\', \\'If a patient with Prostate Cancer, NOS cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\', \\'If a patient with Prostate Cancer, NOS cancer has oncogenic mutations, one recommended therapy is olaparib.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is olaparib,abiraterone,prednisone.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: i have a patient with cdk12 mutated metastatic castrate-resistant prostate cancer which has progressed on adt, abiraterone, and radium. are there any biomarker-directed therapies that he would be eligible for?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Erdheim-Chester Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is cobimetinib.\\', \\'If a patient with Erdheim-Chester Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is cobimetinib.\\', \\'If a patient with Breast Cancer cancer has oncogenic mutations (excluding fusions), one recommended therapy is fulvestrant.\\', \\'If a patient with Rosai-Dorfman Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is cobimetinib.\\', \\'If a patient with Rosai-Dorfman Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is cobimetinib.\\', \\'If a patient with Erdheim-Chester Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is trametinib.\\', \\'If a patient with Erdheim-Chester Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is trametinib.\\', \\'If a patient with Breast Cancer cancer has oncogenic mutations (excluding c420r, e542k, e545a, e545d, e545g, e545k, q546e, q546r, h1047l, h1047r and h1047y), one recommended therapy is alpelisib,fulvestrant.\\', \\'If a patient with Rosai-Dorfman Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is trametinib.\\', \\'If a patient with Rosai-Dorfman Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is trametinib.\\']\\n    ---------------------\\n    \\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\\n    {\\n        \"Status\": \"no_match\",\\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\\n    }\\n    \\n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\\n    {\\n        \"Status\": \"success\",\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\": \\n            \"FDA-approval status\":\\n            \"Link to FDA-approved Label\":\\n            }\\n    }\\n    Query: can we target chek2 mutations for patients with metastatic breast carcinoma?\\n     \\n    ']],\n",
       " [17.83278799057007])"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "run_iterations_rag(\n",
    "    num_iterations=1,#args.num_iter, \n",
    "    data=_QUERY_DF, \n",
    "    context_chunks=_CONTEXT, \n",
    "    db_entity=_DB_ENTITY,\n",
    "    query_entity=_QUERY_ENTITY, \n",
    "    num_vec=10, \n",
    "    index=_INDEX,\n",
    "    client=CLIENT, \n",
    "    model=_MODEL, \n",
    "    model_embed=_MODEL_EMBED, \n",
    "    model_type='gpt',\n",
    "    strategy=5,\n",
    "    max_len=None, \n",
    "    temp=0.0, \n",
    "    random_seed=None\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "5dcc662f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time elapsed for iteration 0: 0.4069 min\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "([['{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Cholangiocarcinoma\",\\n    \"Disease Phase or Condition\": \"Metastatic\",\\n    \"Drug Name\": \"Futibatinib\",\\n    \"Prior Treatment or Resistance Status\": \"Progressed on standard first-line treatments\",\\n    \"Genomic Features\": \"FGFR2 fusion\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/futibatinib\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Neuroblastoma\",\\n    \"Disease Phase or Condition\": \"relapsed high-risk\",\\n    \"Drug Name\": \"ALK inhibitor\",\\n    \"Prior Treatment or Resistance Status\": \"relapsed\",\\n    \"Genomic Features\": \"ALK mutation x\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"B-cell Acute Lymphoblastic Leukemia (B-ALL)\",\\n    \"Disease Phase or Condition\": \"Relapsed\",\\n    \"Drug Name\": \"Blinatumomab\",\\n    \"Prior Treatment or Resistance Status\": \"Relapsed\",\\n    \"Genomic Features\": \"CD19 expression\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/blinatumomab\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Colorectal Cancer\",\\n    \"Disease Phase or Condition\": \"advanced\",\\n    \"Drug Name\": \"adagrasib, cetuximab\",\\n    \"Prior Treatment or Resistance Status\": \"progressed on chemotherapy\",\\n    \"Genomic Features\": \"g12c\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Medullary Thyroid Cancer\",\\n    \"Disease Phase or Condition\": \"Progressive or metastatic\",\\n    \"Drug Name\": \"Selpercatinib\",\\n    \"Prior Treatment or Resistance Status\": \"N/A\",\\n    \"Genomic Features\": \"RET mutation\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/selpercatinib\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Pancreatic Adenocarcinoma\",\\n    \"Disease Phase or Condition\": \"metastatic or unresectable, progressed on at least one line of chemotherapy\",\\n    \"Drug Name\": \"zenocutuzumab\",\\n    \"Prior Treatment or Resistance Status\": \"progressed on chemotherapy\",\\n    \"Genomic Features\": \"NRG1 gene fusion\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/zenocutuzumab\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Rhabdomyosarcoma\",\\n    \"Disease Phase or Condition\": \"TFCP2 fusion positive\",\\n    \"Drug Name\": \"alectinib\",\\n    \"Prior Treatment or Resistance Status\": \"N/A\",\\n    \"Genomic Features\": \"TFCP2 fusion\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Bladder Cancer\",\\n    \"Disease Phase or Condition\": \"metastatic, progressed on chemotherapy\",\\n    \"Drug Name\": \"pembrolizumab, trastuzumab, chemotherapy\",\\n    \"Prior Treatment or Resistance Status\": \"progressed on chemotherapy\",\\n    \"Genomic Features\": \"focal amplification of the jak2/pd-l1 locus\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Lung Adenocarcinoma\",\\n    \"Disease Phase or Condition\": \"Advanced or metastatic non-small cell lung cancer (NSCLC)\",\\n    \"Drug Name\": \"Sotorasib\",\\n    \"Prior Treatment or Resistance Status\": \"Previously treated with at least one systemic therapy\",\\n    \"Genomic Features\": \"KRAS G12C mutation\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sotorasib-lung-cancer\"\\n  },\\n  \"Treatment 2\": {\\n    \"Disease Name\": \"Lung Adenocarcinoma\",\\n    \"Disease Phase or Condition\": \"Advanced or metastatic non-small cell lung cancer (NSCLC)\",\\n    \"Drug Name\": \"Adagrasib\",\\n    \"Prior Treatment or Resistance Status\": \"Previously treated with systemic therapy\",\\n    \"Genomic Features\": \"KRAS G12C mutation\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/adagrasib\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Wilms Tumor\",\\n    \"Disease Phase or Condition\": \"High Grade with WT1 Mutation\",\\n    \"Drug Name\": \"Not specified in provided data\",\\n    \"Prior Treatment or Resistance Status\": \"Not specified in provided data\",\\n    \"Genomic Features\": \"WT1 mutation\",\\n    \"Link to FDA-approved Label\": \"N/A\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Prostate Cancer\",\\n    \"Disease Phase or Condition\": \"metastatic castrate-resistant prostate cancer\",\\n    \"Drug Name\": \"olaparib\",\\n    \"Prior Treatment or Resistance Status\": \"progressed on ADT, abiraterone, and radium\",\\n    \"Genomic Features\": \"CDK12 mutation\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/olaparib\"\\n  }\\n}',\n",
       "   '{\\n  \"Treatment 1\": {\\n    \"Disease Name\": \"Breast Cancer\",\\n    \"Disease Phase or Condition\": \"metastatic\",\\n    \"Drug Name\": \"fulvestrant\",\\n    \"Prior Treatment or Resistance Status\": \"none specified\",\\n    \"Genomic Features\": \"oncogenic mutations (excluding fusions)\",\\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/fulvestrant\"\\n  }\\n}']],\n",
       " [['\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Cholangiocarcinoma cancer has fusions, one recommended therapy is futibatinib.\\', \\'If a patient with Cholangiocarcinoma cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Cholangiocarcinoma cancer has oncogenic mutations, one recommended therapy is lirafugratinib.\\', \\'If a patient with Cholangiocarcinoma cancer has r132s,r132l,r132c,r132h,r132g, one recommended therapy is ivosidenib.\\', \\'If a patient with Intrahepatic Cholangiocarcinoma cancer has r132s,r132l,r132c,r132h,r132g, one recommended therapy is ivosidenib.\\', \\'If a patient with All Solid Tumors cancer has amplification, one recommended therapy is lirafugratinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is fedratinib.\\', \\'If a patient with All Solid Tumors cancer has oncogenic mutations, one recommended therapy is lirafugratinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Pancreatic Cancer cancer has fusions, one recommended therapy is erdafitinib.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: i have a patient with metastatic cholangiocarcinoma and an fgfr2 fusion. this patient has already progressed on standard first-line treatments. are there any approved therapies i should consider?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Neuroblastoma cancer has r1275q, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has r1275l, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1174c, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1174l, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1245v, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1245y, one recommended therapy is lorlatinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is alectinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has i1171n, one recommended therapy is alectinib.\\', \\'If a patient with Inflammatory Myofibroblastic Tumor cancer has fusions, one recommended therapy is alectinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is nvl-655.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: a patient with relapsed high-risk neuroblastoma has alk mutation x. should they receive an alk inhibitor, and if so, which one?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with APL with PML-RARA cancer has pml-rara fusion, one recommended therapy is tretinoin.\\', \\'If a patient with APL with PML-RARA cancer has pml-rara fusion, one recommended therapy is tretinoin,arsenic trioxide.\\', \\'If a patient with APL with PML-RARA cancer has pml-rara fusion, one recommended therapy is arsenic trioxide.\\', \\'If a patient with APL with PML-RARA cancer has pml-rara fusion, one recommended therapy is arsenic trioxide.\\', \\'If a patient with Mastocytosis cancer has d816, one recommended therapy is avapritinib.\\', \\'If a patient with Histiocytosis cancer has v600, one recommended therapy is dabrafenib.\\', \\'If a patient with Neuroblastoma cancer has f1245v, one recommended therapy is lorlatinib.\\', \\'If a patient with Glioma cancer has amplification, one recommended therapy is lapatinib.\\', \\'If a patient with Melanoma cancer has v600, one recommended therapy is vemurafenib,atezolizumab,cobimetinib.\\', \\'If a patient with Histiocytosis cancer has v600, one recommended therapy is vemurafenib.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: for a patient with relapsed b-all that expresses cd19, what targeted treatment options exist?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Colorectal Cancer cancer has g12c, one recommended therapy is adagrasib,cetuximab.\\', \\'If a patient with Colorectal Cancer cancer has g12c, one recommended therapy is sotorasib,cetuximab.\\', \\'If a patient with Colorectal Cancer cancer has g12c, one recommended therapy is adagrasib,panitumumab.\\', \\'If a patient with Colorectal Cancer cancer has g12c, one recommended therapy is sotorasib,panitumumab.\\', \\'If a patient with Anal Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Ampullary Cancer cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Small Bowel Cancer cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Ampullary Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Colorectal Cancer cancer has oncogenic mutations, one recommended therapy is cetuximab.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: what drug combination is approved for adults with kras g12c-mutated advanced colorectal cancer who have progressed on chemotherapy?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Medullary Thyroid Cancer cancer has oncogenic mutations, one recommended therapy is selpercatinib.\\', \\'If a patient with Medullary Thyroid Cancer cancer has oncogenic mutations, one recommended therapy is pralsetinib.\\', \\'If a patient with Thyroid Cancer cancer has fusions, one recommended therapy is selpercatinib.\\', \\'If a patient with Thyroid Cancer cancer has fusions, one recommended therapy is pralsetinib.\\', \\'If a patient with All Solid Tumors cancer has fusions, one recommended therapy is selpercatinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is fedratinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is ruxolitinib.\\', \\'If a patient with Anaplastic Thyroid Cancer cancer has v600e, one recommended therapy is dabrafenib,trametinib.\\', \\'If a patient with All Solid Tumors cancer has fusions, one recommended therapy is repotrectinib.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: if a patient with progressive or metastatic medullary thyroid cancer needs systemic therapy and the tumor has a ret mutation, what is preferred first line treatment?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Pancreatic Adenocarcinoma cancer has fusions, one recommended therapy is zenocutuzumab.\\', \\'If a patient with Acinar Cell Carcinoma of the Pancreas cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with All Solid Tumors cancer has fusions, one recommended therapy is zenocutuzumab.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12d, one recommended therapy is asp3082.\\', \\'If a patient with Acinar Cell Carcinoma of the Pancreas cancer has oncogenic mutations, one recommended therapy is olaparib.\\', \\'If a patient with Acinar Cell Carcinoma of the Pancreas cancer has oncogenic mutations, one recommended therapy is olaparib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with Acinar Cell Carcinoma of the Pancreas cancer has oncogenic mutations, one recommended therapy is rucaparib.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: my patient with metastatic or unresectable pancreatic adenocarcinoma has progressed on at least one line of chemotherapy and was found to have an nrg1 gene fusion via somatic tumor testing. what options are there for subsequent treatment?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Inflammatory Myofibroblastic Tumor cancer has fusions, one recommended therapy is alectinib.\\', \\'If a patient with Inflammatory Myofibroblastic Tumor cancer has fusions, one recommended therapy is ceritinib.\\', \\'If a patient with Inflammatory Myofibroblastic Tumor cancer has fusions, one recommended therapy is brigatinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is ceritinib.\\', \\'If a patient with All Solid Tumors cancer has fusions, one recommended therapy is crizotinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is alectinib.\\', \\'If a patient with Neuroblastoma cancer has f1174c, one recommended therapy is lorlatinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is ceritinib.\\', \\'If a patient with Neuroblastoma cancer has r1275q, one recommended therapy is lorlatinib.\\', \\'If a patient with Non-Small Cell Lung Cancer cancer has fusions, one recommended therapy is ensartinib.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: are alk inhibitors approved for use in tfcp2 fusion positive rhabdomyosarcoma?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Bladder Cancer cancer has oncogenic mutations, one recommended therapy is tazemetostat.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Bladder Cancer cancer has oncogenic mutations, one recommended therapy is cisplatin.\\', \\'If a patient with Esophagogastric Adenocarcinoma cancer has amplification, one recommended therapy is pembrolizumab,trastuzumab,chemotherapy.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is ruxolitinib.\\', \\'If a patient with Bladder Cancer cancer has oncogenic mutations, one recommended therapy is erdafitinib.\\', \\'If a patient with Bladder Cancer cancer has oncogenic mutations, one recommended therapy is erdafitinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is fedratinib.\\', \\'If a patient with Melanoma cancer has v600, one recommended therapy is vemurafenib,atezolizumab,cobimetinib.\\', \\'If a patient with Bladder Cancer cancer has e2014k,e2419k, one recommended therapy is everolimus.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: i have a patient with metastatic bladder cancer who has progressed on chemotherapy. genomics testing revealed a focal amplification of the jak2/pd-l1 locus. what are the treatment options?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Pancreatic Adenocarcinoma cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Ampullary Cancer cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Ampullary Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12a,g12d,g12r,g12s,g12v, one recommended therapy is daraxonrasib.\\', \\'If a patient with Small Bowel Cancer cancer has g12c, one recommended therapy is sotorasib.\\', \\'If a patient with Small Bowel Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Pancreatic Adenocarcinoma cancer has g12d, one recommended therapy is asp3082.\\', \\'If a patient with Anal Cancer cancer has g12c, one recommended therapy is adagrasib.\\', \\'If a patient with Tubular Adenoma of the Colon cancer has g12c, one recommended therapy is adagrasib.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: for a patient with lung adenocarcinoma and a kras g12c mutation, what targeted treatments are approved and for what stage?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Oligodendroglioma cancer has r172k,r172m,r172s,r172w,r172g, one recommended therapy is vorasidenib.\\', \\'If a patient with Astrocytoma cancer has r172k,r172m,r172s,r172w,r172g, one recommended therapy is vorasidenib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is pemigatinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is ruxolitinib.\\', \\'If a patient with Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2 cancer has fusions, one recommended therapy is fedratinib.\\', \\'If a patient with All Solid Tumors cancer has f617l, one recommended therapy is larotrectinib.\\', \\'If a patient with Neuroblastoma cancer has r1275q, one recommended therapy is lorlatinib.\\', \\'If a patient with Neuroblastoma cancer has f1174l, one recommended therapy is lorlatinib.\\', \\'If a patient with All Solid Tumors cancer has g696a, one recommended therapy is larotrectinib.\\', \\'If a patient with All Solid Tumors cancer has amplification, one recommended therapy is blu-222.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: what can target high grade wilms tumor with wt1 mutation\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is olaparib.\\', \\'If a patient with Prostate Cancer, NOS cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\', \\'If a patient with Prostate Cancer, NOS cancer has oncogenic mutations, one recommended therapy is olaparib.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is olaparib,abiraterone,prednisone.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is rucaparib.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\', \\'If a patient with Prostate Cancer cancer has oncogenic mutations, one recommended therapy is talazoparib,enzalutamide.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: i have a patient with cdk12 mutated metastatic castrate-resistant prostate cancer which has progressed on adt, abiraterone, and radium. are there any biomarker-directed therapies that he would be eligible for?\\n     \\n    ',\n",
       "   '\\n    Context information is below.\\n    ---------------------\\n    [\\'If a patient with Erdheim-Chester Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is cobimetinib.\\', \\'If a patient with Erdheim-Chester Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is cobimetinib.\\', \\'If a patient with Breast Cancer cancer has oncogenic mutations (excluding fusions), one recommended therapy is fulvestrant.\\', \\'If a patient with Rosai-Dorfman Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is cobimetinib.\\', \\'If a patient with Rosai-Dorfman Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is cobimetinib.\\', \\'If a patient with Erdheim-Chester Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is trametinib.\\', \\'If a patient with Erdheim-Chester Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is trametinib.\\', \\'If a patient with Breast Cancer cancer has oncogenic mutations (excluding c420r, e542k, e545a, e545d, e545g, e545k, q546e, q546r, h1047l, h1047r and h1047y), one recommended therapy is alpelisib,fulvestrant.\\', \\'If a patient with Rosai-Dorfman Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is trametinib.\\', \\'If a patient with Rosai-Dorfman Disease cancer has oncogenic mutations (excluding v600), one recommended therapy is trametinib.\\']\\n    ---------------------\\n    Please provide each treatment as a json format with the following JSON schema.\\n    {\\n        \"Treatment 1\": {\\n            \"Disease Name\": ,\\n            \"Disease Phase or Condition\": ,\\n            \"Drug Name\": ,\\n            \"Prior Treatment or Resistance Status\": ,\\n            \"Genomic Features\":\\n            \"Link to FDA-approved Label\": \\n            }\\n    }\\n    Query: can we target chek2 mutations for patients with metastatic breast carcinoma?\\n     \\n    ']],\n",
       " [24.412163972854614])"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "run_iterations_rag(\n",
    "    num_iterations=1,#args.num_iter, \n",
    "    data=_QUERY_DF, \n",
    "    context_chunks=_CONTEXT, \n",
    "    db_entity=_DB_ENTITY,\n",
    "    query_entity=_QUERY_ENTITY, \n",
    "    num_vec=10, \n",
    "    index=_INDEX,\n",
    "    client=CLIENT, \n",
    "    model=_MODEL, \n",
    "    model_embed=_MODEL_EMBED, \n",
    "    model_type='gpt',\n",
    "    strategy=0,\n",
    "    max_len=None, \n",
    "    temp=0.0, \n",
    "    random_seed=None\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2b639b7f",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
